Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension

Expert Review of Clinical Pharmacology

Volumn 4, Issue 2, 2011, Pages 197-205

  John, Julie ^a   Palevsky, Harold ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

arachidonic acid metabolite; iloprost; prostacyclin; prostaglandin; pulmonary arterial hypertension

Indexed keywords

ADENOSINE; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; DIGOXIN; ENDOTHELIN 1; ILOPROST; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E1; SEROTONIN; SILDENAFIL; THROMBOXANE; TYVASO; UNCLASSIFIED DRUG; UNIPROST;

ADD ON THERAPY; BACKACHE; BRADYCARDIA; BRONCHOSPASM; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; EDEMA; EPISTAXIS; FLU LIKE SYNDROME; FLUSHING; FUNCTIONAL STATUS; GINGIVA BLEEDING; HEADACHE; HUMAN; HYPOTENSION; JAW PAIN; LACTATION; LIVER DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NAUSEA; NONHUMAN; PREGNANCY; PULMONARY HYPERTENSION; RECTUM HEMORRHAGE; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; SYMPTOM; SYNCOPE; VOMITING; WHEEZING;

ADMINISTRATION, INHALATION; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 79952763662     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.136     Document Type: Review

References (67)

1. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl.), 7S-10S (2004).
2. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(12 Suppl.), S40-S47 (2004).
3. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J. Am. Coll. Cardiol. 53, 1-43 (2009).
4. Park MH. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheter Cardiovascular Intervention 71(2), 205-213 (2008).
5. Yuan JXJ, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 111, 534-538 (2005).
6. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. 107, 216-223 (1987).
7. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Ann. Intern. Med. 115, 343-349 (1991).
8. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin. Chest Med. 23(1), 1-22 (2007).
9. Thenappan T, Shah SJ, Rich S. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur. Respir. J. 30, 1103-1110 (2007).
10. Humber M. Update in pulmonary arterial hypertension 2007. Am. J. Respir. Crit. Care Med. 177, 574-579 (2008).
11. Simonneau G, Robbins, IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54, S43-S54 (2009).
12. Channick RN, Olschewski H, Seeger W et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 48, 1433-1437 (2006).
13. Voswinckel R, Reichenberger F, Enke B et al. Acute effects of the combination of sildenafil and inhaled treprostinil on hemodynamics and gas exchange in pulmonary hypertension. Pulm. Pharmacol. Ther. 21, 824-832 (2008).
14. McLaughlin V, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol. 55, 1915-1922 (2010).
15. Ewert R, Schaper C, Halank M et al. Inhalative iloprost-pharmacology and clinical application. Expert Opin. Pharmacother. 10(13), 1-13 (2009).
16. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol. Rep. 60, 3-11 (2008).
17. Bos CL, Richel DJ, Ritsema T et al. Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol. 36, 1187-1205 (2004).
18. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir. Med. 104(1), 9-21 (2009).
19. Beghetti M, Reber G, de Moerloose P et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur. Respir. J. 19(3), 518-524 (2002).
20. Fischer CA, Kappa JR, Sinha AK et al. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function. J. Lab. Clin. Med. 109(2), 184 (1987).
21. McLaughlin VV, Presberg KW, Doyle RL et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126, 78-92 (2004).
22. Badesch DB, Abman SH, Simonneau G. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131, 1917-1928 (2007).
23. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. J. Cardiol. 37, 110-111 (2001).
24. McGoon M, Gutterman D, Steen V et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. Chest 126, 145-305 (2004).
25. Qutayba H, Shannon J, Martin J. Physiological basis of respiratory disease. Eur. Respir. J. 27, 243 (2006).
26. Mclaughlin V, McGoon M. Pulmonary arterial hypertension. Circulation 114(13), 1417-1431 (2006).
27. Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol. 35, 176-182 (2000).
28. Opitz CF, Wensel R, Bettmann M et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost admininstered by either infusion or inhalation. Eur. Heart J. 24, 356-365 (2003).
29. Blumberg FC, Riegger GAJ, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 121, 1566-1571 (2002).
30. Cowley AJ, Heptinstall S, Hamptom JR. Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behavior in man. J. Thromb. Haemost. 53(1), 90-94 (1985).
31. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322-329 (2002).
32. Macherndl S, Kneussl M, Baumgartner H et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur. Respir. J. 17(1) 8-13 (2001).
33. Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 28, 691-694 (2006).
34. Opitz CF, Wensel R, Winkler R et al. Clinical efficacy and survival with inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J. 26, 1895-1902 (2005).
35. Clapp LH, Finney P, Turcato S et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Mol. Biol. 26(2), 194-201 (2002).
36. Schermuly RT, Schulz A, Ghofrani HA et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J. Pharmacol. Exp. Ther. 303(2), 741-745 (2002).
37. Gessler T, Schmehl T, Hoper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J. 17, 14-19 (2001).
38. Olschewski H, Rose F, Scermuly R et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol. Ther. 102, 139-153 (2004).
39. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 43(6) 889-924 (1992).
40. Goldsmith DR, Wagstaff JA. Inhaled iloprost in primary pulmonary hypertension. Drugs 64, 763-773 (2004).
41. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. Eur. J. Clin. Pharmacol. 32, 597-605 (1987).
42. Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices in severe pulmonary hypertension. Chest 124, 1294-1304 (2003).
43. Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med. 124, 820-824 (1996).
44. Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med. 342, 1866-1870 (2000).
45. Krug S, Seyfarth H, Hagedorff A, Wirtz H. Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. Eur. J. Gastroenterol. Hepatol. 19, 1140-1143 (2007).
46. Hildebrand M, Krause W, Angeli P et al. Pharmacokinetic of iloprost in patients with hepatic dysfunction. Int. J. Clin. Pharmacol. Ther. Toxicol. 10, 430-434 (1990).
47. Minder S, Fischler M, Muellhaupt B et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur. Respir. J. 24, 703-707 (2004).
48. Hildebrand M, Krause W, Fabian H et al. Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance hemodialysis. Int. J. Clin. Pharmacol. Res. 10, 285-292 (1990).
49. Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary arterial hypertension in children. Vasc. Health Risk Manag. 5, 325-331 (2009).
50. Huang S, Desantis ERH. Treatment of pulmonary arterial hypertension in pregnancy. Am. J. Health Syst Pharm. 64, 1922-1925 (2007).
51. Wong PS, Constantinides S, Kennedy CR et al. Primary pulmonary hypertension in pregnancy. J. R. Soc. Med. 94, 523-526 (2001).
52. Winterhalter M, Simon A, Fischer S et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J. Cardiothorac. Vasc. Anesth. 22, 406-413 (2008).
53. Petkov V, Ziesche R, Mosgoeller W et al. Aerosolized iloprost improves pulmonary hemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 56, 734-736 (2001).
54. McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174, 1257-1263 (2006).
55. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur. Respir. Rev. 18, 2-34 (2009).
56. Olschewski H, Hoper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir. Med. 2010 104, 731-740 (2004).
57. Olschewski H, Nikkho S, Behr J et al. Long-term survival in patients with pulmonary hypertension inhaling iloprost. Eur. Heart J. 24, 482 (abstract 2567) (2003).
58. Ghofrani HA, Friese G, Discher T et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur. Respir. J. 23, 321-326 (2004).
59. Cicalili S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr. HIV Res. 7, 589-596 (2009).
60. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS 22, S55-S62 (2008).
61. The US FDA Center for Evaluation and Research. Tyvaso www.fda.gov/Drugs/NewsEvents/ UCM130961 (Accessed 6 September 2010)
62. Ventavis prescribing information www.4ventavis.com (Accessed 3 December 2010)
63. The US FDA Center for Evaluation and Research. Ventavis www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails (Accessed 21 January 2010)
64. Medsafe site for New Zealand www.medsafe.govt.nz (Accessed 21 January 2010)
65. The European Agency for the Evaluation of Medicinal Products. Ventavis: summary of product characteristics www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000474/human-med-001133.jsp&mid= WC0b01ac058001d125&murl=menus/medicines/medicines.jsp&jsenabled=true (Accessed 21 January 2010)
66. Ventavis (iloprost) package insert www.4ventavis.com/pdf/Vent- PromoPIUpdate6-10-VV6334.pdf (Accessed 21 January 2010)
67. Adverse Drug Reaction published by the Health Products Regulation Group, HAS and the HAS Pharmacovigilance Advisory Committee www.hsa.gov.sg/publish/ hsaportal/en/health-products-regulation/safety-information/pharmacovigilance. html (Accessed 21 January 2010)